By 2020, about half of the money spent on the pharmacy benefit will be on specialty drugs, and these medications will be prescribed for fewer than 2% of patients, according to Aimee Tharaldson, PharmD, a senior clinical consultant in emerging therapeutics at Express Scripts.
Novel therapies will continue to garner high price tags, but specialty drugmakers can expect increased competition in the coming years as 64 patents for specialty molecules and 73 patents for biologicals